Non-invasive detection kit for early diagnosis of Alzheimer's disease

Wing Ho Chau; Chung Yan Cheung; Hung Wing Li; Man Shing Wong

doi:10.1016/j.inv.2022.100004

Non-invasive detection kit for early diagnosis of Alzheimer's disease

Wing Ho Chau
, Chung Yan Cheung
, Hung Wing Li^*
, Man Shing Wong^*

^*Corresponding author for this work

Department of Chemistry

Research output: Contribution to journal › Journal article › peer-review

Abstract

The present invention discloses a new Alzheimer's disease (AD) diagnostic kit that tests blood, saliva and urine, providing a faster, more sensitive, affordable and non-invasive way than conventional method of detection. This detection assay only requires a few microliters of the body fluids to quantify the target AD-related protein biomarkers. The assay is based on the immunoreaction between the target protein biomarkers and their corresponding pair of antibodies followed by fluorescence labelling with a newly developed cyanine turn-on fluorophore. The intensity of the fluorescence signal can act as an index to evaluate the severity of AD. Therefore, the present invention can serve as an analytical tool for early diagnosis, progression monitoring and staging.

Original language	English
Article number	100004
Number of pages	7
Journal	Invention Disclosure
Volume	2
Early online date	9 Jun 2022
DOIs	https://doi.org/10.1016/j.inv.2022.100004
Publication status	Published - 2 Jul 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

User-Defined Keywords

Alzheimer's disease
Biomarker
Diagnostic
Fluorophore
Nanoprobe
Non-invasive

Access to Document

10.1016/j.inv.2022.100004

Cite this

@article{b0c2be9b82434f0cb33476317116be7b,

title = "Non-invasive detection kit for early diagnosis of Alzheimer's disease",

abstract = "The present invention discloses a new Alzheimer's disease (AD) diagnostic kit that tests blood, saliva and urine, providing a faster, more sensitive, affordable and non-invasive way than conventional method of detection. This detection assay only requires a few microliters of the body fluids to quantify the target AD-related protein biomarkers. The assay is based on the immunoreaction between the target protein biomarkers and their corresponding pair of antibodies followed by fluorescence labelling with a newly developed cyanine turn-on fluorophore. The intensity of the fluorescence signal can act as an index to evaluate the severity of AD. Therefore, the present invention can serve as an analytical tool for early diagnosis, progression monitoring and staging.",

keywords = "Alzheimer's disease, Biomarker, Diagnostic, Fluorophore, Nanoprobe, Non-invasive",

author = "Chau, \{Wing Ho\} and Cheung, \{Chung Yan\} and Li, \{Hung Wing\} and Wong, \{Man Shing\}",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

month = jul,

day = "2",

doi = "10.1016/j.inv.2022.100004",

language = "English",

volume = "2",

journal = "Invention Disclosure",

issn = "2772-4441",

publisher = "Elsevier",

}

TY - JOUR

T1 - Non-invasive detection kit for early diagnosis of Alzheimer's disease

AU - Chau, Wing Ho

AU - Cheung, Chung Yan

AU - Li, Hung Wing

AU - Wong, Man Shing

PY - 2022/7/2

Y1 - 2022/7/2

N2 - The present invention discloses a new Alzheimer's disease (AD) diagnostic kit that tests blood, saliva and urine, providing a faster, more sensitive, affordable and non-invasive way than conventional method of detection. This detection assay only requires a few microliters of the body fluids to quantify the target AD-related protein biomarkers. The assay is based on the immunoreaction between the target protein biomarkers and their corresponding pair of antibodies followed by fluorescence labelling with a newly developed cyanine turn-on fluorophore. The intensity of the fluorescence signal can act as an index to evaluate the severity of AD. Therefore, the present invention can serve as an analytical tool for early diagnosis, progression monitoring and staging.

AB - The present invention discloses a new Alzheimer's disease (AD) diagnostic kit that tests blood, saliva and urine, providing a faster, more sensitive, affordable and non-invasive way than conventional method of detection. This detection assay only requires a few microliters of the body fluids to quantify the target AD-related protein biomarkers. The assay is based on the immunoreaction between the target protein biomarkers and their corresponding pair of antibodies followed by fluorescence labelling with a newly developed cyanine turn-on fluorophore. The intensity of the fluorescence signal can act as an index to evaluate the severity of AD. Therefore, the present invention can serve as an analytical tool for early diagnosis, progression monitoring and staging.

KW - Alzheimer's disease

KW - Biomarker

KW - Diagnostic

KW - Fluorophore

KW - Nanoprobe

KW - Non-invasive

UR - https://www.scopus.com/pages/publications/105018879511

U2 - 10.1016/j.inv.2022.100004

DO - 10.1016/j.inv.2022.100004

M3 - Journal article

AN - SCOPUS:105018879511

SN - 2772-4441

VL - 2

JO - Invention Disclosure

JF - Invention Disclosure

M1 - 100004

ER -

Non-invasive detection kit for early diagnosis of Alzheimer's disease

Abstract

UN SDGs

User-Defined Keywords

Access to Document

Other files and links

Fingerprint

Cite this